CBCF funding to support deoxymab brain cancer development
Filed with ASX · · 4 pages · English
Melbourne, Australia; 3 June 2022: Patrys Limited (ASX: PAB, “Patrys” or the “Company”), a therapeutic antibody development company, is pleased to announce that Telethon Kids Institute has been awarded $250,000 in funding from the inaugural Clinical Accelerator fund of Cure Brain Cancer Foundation to support research on potential therapeutic applications for Patrys’ PAT-DX1 and PAT- DX3 deoxymabs
Earlier from Patrys
- Appendix 4C - Quarterly - 31 March 2022
- Application for quotation of securities - PAB
- Stable Cell Line for Production of PAT-DX3 Established
- Appendix 4D - Half Year Accounts - 31 December 2021
- Appendix 4C - Quarterly - 31 December 2021
Later from Patrys
- New Mechanism By Which PAT-DX1 May Reduce Cancer Metastasis
- PAT-DX1 Engineering Run Successfully Completed
- Appendix 4C - Quarterly - 30 June 2022
- PAT-DX1/Radiation Combination Improves Brain Cancer Survival
- New Research Grant For Deoxymabs in Metastatic Breast Cancer
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys